Introduction: Fibrinogen is a complex molecule comprised of two sets of Aα, Bβ, and γ
| INTRODUC TI ON
The mature fibrinogen molecule is encoded by three genes, fibrinogen alpha chain (FGA), fibrinogen beta chain (FGB), and fibrinogen gamma chain (FGG), located contiguously on chromosome 4q23. 5 Mutations in these genes can lead to quantitative (afibrinogenemia and hypofibrinogenemia) or qualitative (dysfibrinogenemia and hypodysfibrinogenemia) fibrinogen abnormalities which are diagnosed by plasma fibrinogen antigen and activity assays. 6 Congenital afibrinogenemia (CAF) is characterized by undetectable plasma fibrinogen antigen and bleeding. It is inherited in an autosomal recessive manner with mutations or deletions commonly located in FGA. 7, 8 Hypofibrinogenemia is characterized by a decreased plasma fibrinogen antigen level that is proportionally related to decreased fibrinogen function, with phenotypes ranging from asymptomatic to mild or moderate bleeding. Patients with hypofibrinogenemia are often heterozygous carriers of afibrinogenemia mutations. 6 Approximately 30% of patients with CAF or severe hypofibrinogenemia develop thrombosis, which may be due to embolism of an unstable thrombus. 9, 10 Congenital dysfibrinogenemia (CD) is a qualitative defect classified by decreased functional activity despite normal antigen levels. 11 CD mutations are often inherited in an autosomal dominant manner and are commonly found in exon 2 of FGA, which encodes the thrombin cleavage site for EA exposure enabling EA-D interactions, or in exon 8 of FGG, which is involved in D:D end-to-end assembly of fibrin. 12 Clinical presentation is highly variable 13 and approximately 50% of CD patients are diagnosed incidentally. 14, 15 Hypodysfibrinogenemia is defined by disproportionately decreased fibrinogen antigen and decreased function. 5 Patients with hypodysfibrinogenemia patients can be asymptomatic or have bleeding and/or clotting events.
Clinically, the diagnosis of fibrinogen disorders is based on antigen and functional assays, often in addition to thrombin time (TT) and reptilase time (RT). However, phenotypic variability and lack of correlation between laboratory values, symptoms manifestation and disease severity complicate diagnosis and consequently, clinical management.
In this study, we evaluated 31 patients with fibrinogen disorders for disease-causing mutations, performed molecular modeling to elucidate the function of amino acid residues from novel variants, and attempted to correlate these genetic variants with fibrinogen levels and clinical presentation. These data contribute to understanding the function of fibrinogen in thrombosis and hemostasis. 
Essentials
• Fibrinogen Disorders are characterized by variable expressivity.
• Patients with fibrinogen disorders can present with bleeding, thrombosis, or both.
• As previously reported, genotype-phenotype correlations are difficult to establish.
• Molecular modeling may help to further understand the effects of mutations on the mature fibrinogen protein.
| METHODS

| Subject identification
Subjects with fibrinogen disorders were identified for this study by the presence of: (i) a previously diagnosed congenital fibrinogen deficiency; (ii) abnormal laboratory results (either symptomatic or asymptomatic and diagnosed during routine or presurgical screenings); and/or (iii) a positive family history of a fibrinogen disorder. Thirty-one subjects (20 subjects from 7 families, in addition to 11 other unrelated individuals), were identified at the Hemostasis and Thrombosis Centers in Denver, Colorado;
Houston, Texas; and North Carolina in the United States; and in Cordoba, Argentina. 
| Fibrinogen measurements
| DNA sequencing
Sanger sequencing was performed for FGA, FGB, and FGG on genomic DNA to evaluate for disease-causing mutations. DNA from buffy coat or whole blood samples was isolated using a commercially available FlexiGene DNA kit (Qiagen Sciences Inc., Germantown, MD, USA) following instructions from the published protocol. The exons, intron-exon boundaries, and core promoter regions of the fibrinogen genes were amplified by Polymerase Chain Reaction (PCR) using the G-storm thermal cycler (G-storm, Somerset, UK). Primers were designed using the published FGA, FGB, and FGG sequences and are available upon request. PCR products were purified using ExoSap-IT (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. Nucleotide sequences were determined using the Sanger sequencing method as previously described. 19 Mutations were compared against previously described mutations as reported by Ensembl be/HSF/) was used to evaluate the potential effect of the variant.
| In silico molecular modeling
Molecular modeling simulations were conducted using the Accelrys Discovery implicit solvent model. 22 Predicted protein-protein interactions between the minimized wild-type and/or mutant fibrinogen fragment D structures were calculated using the ZDock algorithm. 23 The ZRank scoring function was used to calculate the interaction energies of the resulting predicted protein complexes and represents a combination of van der Waals attractive and repulsive energies, short and long range repulsive and attractive energies, and desolvation. 24 Similarity of the predicted protein complexes to the crystal structure (1FZB) was determined by calculating the root mean square deviation (RMSD) using the crystal structure as the reference. 25 The three poses with the lowest RMSD values (ie, the greatest similarity to the crystal structure) were selected from each group for the energy comparison.
Protein structures were rendered in Lightwave 3D 2015.3 (NewTek, Inc., San Antonio, TX; http://www.lightwave3d.com). (Table 1) 
| RESULTS
| Clinical data
| Patients with congenital afibrinogenemia
All of the subjects with CAF demonstrated bleeding early in life. 
| Patients with congenital dysfibrinogenemia
Subject 5 suffered from an acute myocardial infarction at age 59, while on oral anticoagulation. Subject 7 suffered from a lower extremity DVT after knee surgery at age 62. Subject 9 had excessive perioperative bleeding. Subject 11, suffered a left cerebral arterial stroke (likely in utero) and was diagnosed with fibrinogen deficiency shortly after birth. She also showed spontaneous and perioperative bleeding requiring fibrinogen replacement. The father, subject 10, suffered from mild mucosal bleeding and developed an unprovoked lower extremity DVT at age 49. They are both negative for other known thrombophilia. Subject 12 had a spontaneous PE at age 43. He remains on lifelong anticoagulation. were asymptomatic and were diagnosed with fibrinogen abnormalities incidentally or during pre-surgical screenings.
| Patients with hypodysfibrinogenemia
Subject 18 experienced excessive bleeding necessitating a transfusion following a frenulum tear at age 5. Both the mother, and father, subjects 17 and 29, respectively, are asymptomatic. Subject 19 is asymptomatic. Subject 20 has excessive oral bleeding and menorrhagia. 
| Patients with hypofibrinogenemia
| Sequencing results
Mutations were identified in 29 out of 31 patients (93.5%) ( Table 2) .
Seventeen different mutations in 29 patients were found: 6 novel and 11 previously described variants, in all 3 of the fibrinogen genes ( Figure 1 ). There were 12 missense mutations, 2 nonsense mutations, 2 splice site mutations, and 1 insertion/frameshift mutation.
Novel The FGA Arg16 mutation has been previously described as a mutation hotspot in dysfibrinogenemia as it lies in the thrombin cleavage site of fibrinopeptide A, delaying EA exposure and fibrin formation. Interestingly, patients who were heterozygous for this mutation have a similar phenotype to the one patient who was compound heterozygous for this mutation and a null mutation on the other FGA allele, indicating that a heterozygous FGA Arg16 mutation might be sufficient to induce a phenotype, as has been previously reported. 31 
| FGB
A novel mutation found in FGB was a heterozygous p.Arg455Lys mutation. The majority of subjects with heterozygous FGB mutations had hypofibrinogenemia (67%), one had hypodysfibrinogenemia, and one had normal fibrinogen levels. Two out of six patients with FGB mutations were symptomatic with bleeding, the remainder were asymptomatic.
| FGG
Novel mutations found in FGG were: IVS6-12A>G and p.Ala289Asp.
Although two out of the three patients with CAF had mutations in the FGA gene, 32 one subject with CAF had a compound heterozygous mutations in FGG. One missense (p.Lys85X), previously reported and one novel splice-site mutation (IVS6-12A>G), both predicted to result in non-functional gene products of FGG. 9 Seven patients had mutations in the C-terminus region of FGG, a mutation hotspot for variants causing dysfibrinogenemia and a region that functions in D:D interactions, which occur in amino acids 275-300 of the FGG. 6, 33 Two family members and three other unrelated patients had the previously described Bergamo II mutation (FGG p.Arg275His) and two had a novel mutation (FGG p.Ala289Asp) in this region. 34 The p.Arg275His mutation disrupts D:D interactions and thus interrupts the fibrin alignment in the conversion from fibrinogen to fibrin. symptoms (n = 2), suggesting variable expressivity or other genetic or environmental modifiers of the phenotype. The two related patients, 10 and 11, had a heterozygous FGG p.Ala289Asp mutation located in the same C-terminus region as the Bergamo II mutation and had hypofibrinogenemia (defined by laboratory standards prior to genetic studies) with mild bleeding and unprovoked thrombotic events.
| Molecular modeling
To gain mechanistic insight into the functional relevance of the four missense mutations FGG p.Ala289Asp, FGB p.Gln189Arg, FGB p.Gly272Arg, FGB p.Arg455Lys, computational molecular modeling was performed to examine the potential structural and functional ef- Overall, the in silico modeling suggests that p.Ala289Asp mutation might lead to a more rapid or stronger interaction between fibrinogen molecules, and could account for the thrombotic propensity in the patients with this mutation. Increased rigidity of the fibrin clot has been found to impair the access of fibrinolytic enzymes to fibrin, resulting in a higher incidence of thrombosis. 35 In contrast, more porous, flexible fibrin networks have been associated with increased bleeding tendencies. 36 The two Bβ chain mutants FGB p.Gly272Arg, FGB p.Arg455Lys
were predicted by in silico modeling to induce conformational changes to the fibrinogen structure by altering electrostatic and hydrogen bond interactions. However, the observed changes do not appear to impact the protein-protein interactions between fibrin(ogen) molecules at the D-D interaction interface ( Figure 3 and data not shown). This is consistent with the clinical phenotype of a mild bleeding tendency and no thrombotic events observed in the subjects with these specific FGB mutations. Interestingly, the FGB p.Gly272Arg mutant, despite representing a drastic change in residue identity, occurs in a region of the protein that can accommodate the much bulkier side chain.
Conversely, the FGB p.Arg455Lys mutant represents a relatively conservative change, yet it decreases the coordination of the surrounding charged Glu residues via the loss of electrostatic, pi-cation, 
| Splice site prediction
According to Human Splicing Finder (http://umd.be/HSF3/), the FGG IVS6-12A>G variant effects the acceptor sites at the 3' end of intron 6. It alters the wildtype acceptor site and is predicted to activate an intronic cryptic acceptor site 12 nucleotides upstream of exon 7, which could potentially alter splicing.
| DISCUSSION
The clinical presentation of fibrinogen disorders does not show a consistent correlation with fibrinogen levels, functional assays, or genotype. Results in our cohort were not much different. We did not find clear correlation between the mutations described and any of the functional laboratory analyses or clinical presentation. In the work presented here, subjects with CAF had excessive bleeding or both bleeding and clotting events, while subjects with hypodysfibrinogenemia experienced bleeding or no symptoms. There were asymptomatic subjects in every disease category, except for CAF. and have been associated with bleeding and thrombosis. 37, 38 There are several limitations to this study. For example, the rigidity and flexibility assessments derived from molecular modeling experiments in this study reflect the properties of fibrinogen in the static state and there could be differences when extrapolating the static function and applying it to the dynamic environment.
DNA microarrays were not used to look for larger deletions and insertions that have been reported in some patients with fibrinogen deficiencies (http://site.geht.org/base-fibrinogene/) so there is the possibility that these types of mutations were undetected in some of these individuals. Finally, there is a possibility that the two patients for which a mutation could not be found or the patients with mutations without predicted damaging effects have an acquired fibrinogen deficiency, although this is less likely when taking age of presentation and clinical history into account.
| CONCLUSION
Fibrinogen disorders are difficult to characterize due to their phe- 
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